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HBV particles with genome derived from spliced mRNAs accumulate in patients with virus-derived
severe liver necrosis and ﬁbrosis. We investigated the role of an intronic element (intronic splicing
silencer-long, ISSL) on splicing of HBV minigene transcripts. Removal of the entire ISSL showed two-
fold increase in splicing while shorter deletions within ISSL indicated isolated clusters of activator
and repressor domains. Activator domains stimulated splicing in presence of PRE, a long HBV 30
exon and even when present in a heterologous context. Mutations in the repressor domain unex-
pectedly augmented repression. The role of this intronic splicing regulatory element could be
important for HBV pathogenesis.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction inate. The SP1 product is obtained by removal of intron with 50 do-Hepatitis B virus (HBV), a member of the hepadnaviridae family,
is a 42 nm particle with an enveloped 28 nm nucleocapsid. Tran-
scription on the HBV genome by host RNA polymerase II produces
30-coterminal pregenomic/precore RNA (pgRNA, 3.5 kb) and three
subgenomic RNAs (2.4, 2.1 and 0.8 kb) [1]. Individual promoters
and related enhancer elements that are regulated by ubiquitous
or liver enriched transcription factors, drive transcription of these
viral RNAs [2].
Splicing of viral transcripts in hepadnaviridiae family has di-
verse effects in viral life cycle. Replication of duck hepatitis B virus
(DHBV) in infected primary duck hepatocytes and ducks requires a
spliced mRNA [3]. Even though no direct role of splicing could be
established for HBV replication [4], the load of defective HBV par-
ticles with shortened genome increased with liver necroinﬂamma-
tion and ﬁbrosis [5]. In cultured hepatocytes, about 50% DNA
within intracellular capsids is derived from spliced RNAs [6]. In pa-
tient sera and HBV infected cultured hepatocytes, eleven smaller
than full-length genomes are generated from spliced pgRNA
[7,8]. Of these spliced RNAs, two products (SP1 and SP2) predom-chemical Societies. Published by E
egenomic RNA; ISSL, intronic
tory element; HBSP, hepatitis
scriptase-polymerase chain
h).nor and 30 acceptor sites positioned at 2447nt and 489nt,
respectively, but generation of SP2 requires the donor at 2067nt
and the same acceptor site. The search for cis- and trans-acting fac-
tors regulating pgRNA splicing has identiﬁed both activator and
repressor regions in Post-transcriptional Regulatory Element
(PRE) present in the 30 exon of pgRNA [9]. Recently a double-hair-
pin structure in PRE, when placed in a heterologous intron, si-
lenced splicing in a structure and position-dependent fashion
[10]. However effect of HBV intronic elements in splicing of a
homologous transcript has never been reported.
At least two proteins encoded by spliced HBV RNAs are found in
patient sera and cultured hepatocytes. An endoglycosylase H
(endo-H) sensitive 43 kDa polymerase-surface fusion protein
translated from a HBV spliced RNA was reported in cells expressing
HBV P protein. HBSP, encoded by a 2.2 kb singly spliced mRNA gen-
erated by the same splice sites used for generating SP1 species
[11], bound to the ﬁbrinogen c-chain and inhibited ﬁbrin forma-
tion [12]. Taken together the role of splicing in HBV infection re-
mains a very crucial unanswered question.
To gain insight of how intronic splicing signals dictate splicing
in HBV, we investigated the role of an intronic element (intronic
splicing silencer-long, ISSL) with a pronounced secondary structure
in homologous minigene context. The minigene transcript is very
similar to the HBSP pre-mRNA and thus should recapitulate the
events leading to its processing. Our data reveal that the ISSL is
actually composed of interspersed repressor and activator do-
mains. The activator domains could stimulate splicing even whenlsevier B.V. All rights reserved.
Fig. 1. Construction of the basal minigene, CPS. The 50 and 30-splice sites in pgRNA
and their positions in HBV genes are indicated. ISSL was deleted from CPS
(CPSDISSL), when indicated (upper panel). Arrows show location of the primers
used for ampliﬁcation of cDNA. Primers for real-time PCR for identiﬁcation of
spliced and total minigene transcripts are shown in lower panel.
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exon. Moreover these activator domains were also functional in a
heterologous pre-mRNA. A separate repressor motif within the in-
tron was also identiﬁed. To our knowledge this is the ﬁrst report of
cis-acting intronic splicing regulators from HBV RNA.
2. Materials and methods
2.1. Cell lines and oligonucleotides
HuH7 cell line was maintained in Dulbecco’s modiﬁed Eagle’s
medium with 10% fetal bovine serum. The primers used in cloning
and PCR are depicted in Supplementary Table 1.
2.2. Preparation of minigene constructs
Different regions of the HBV genomewere ampliﬁed from a plas-
mid containing the entire HBV sequence (NCBI No. AY945307) and
cloned in pcDNA 3.1(+) expression vector (Invitrogen) under CMV-
IE promoter. CPS, the basal construct contained sequences spanning
2231–3182 bp followed by 20–621 bp of HBV genome to include
the nucleotide positions 2447 and 489 as splice donor and acceptor
sites with a 1204nt intron separating them. CPS and CPSISSLDISR1
backgrounds were used for PCR with mutagenic primers to gener-
ate ISSLM mutants. PRE (1151–1684nt) and 30 exonic region of
pgRNA (622–1800nt) were inserted downstream of CPS by EcoRI
and KpnI sites to construct CPSPRE and CPSpg minigenes respec-
tively. For reporter assays using pCI-neo mammalian expression
vector (Promega), respective primer pairs were annealed (Supple-
mentary Table I), and inserted into the intron present in the vector
backbone. All the constructs were conﬁrmed by DNA sequencing.
2.3. Transfection
Transient transfections were performed in 6-well plates by
CaCl2 using standard protocols. Each well typically received a mix-
ture of 2 lg of test plasmid, 1 lg of pEGFP-C1 (Clontech), and 2 lg
of pUC19. Total RNA was isolated 48 hours post-transfection using
TRI reagent (Sigma) following manufacturer’s instructions.
2.4. Semiquantitative determination of transcripts
Reverse transcription of isolated total RNA was done with ran-
domhexamers. Hp8 andHp2 primer pair was used for ampliﬁcation
of cDNA from precursor RNA and Hp1 and Hp2 pair was used for
ampliﬁcation of cDNA from spliced RNA. Serial 10-fold dilutions
of target RNA was simultaneously assayed alongside the cellular
RNAs to ascertain that the ampliﬁcation of the products was on
the exponential phase. Each RNA sample was normalized with re-
spect to GFP and GAPDH transcripts. All the tubes were simulta-
neously PCR ampliﬁed with [a-32P]dCTP and analyzed in 6% non-
denaturing polyacrylamide gel. To compare the band intensities
across multiple gels, all the gels under analysis were exposed to-
gether to a phosphorimager screen and analyzed by ImageQuant
TL software. Splicing efﬁciency was calculated as [pixel value of
spliced/pixel values of (spliced + unspliced)] for each sample.
Splicing in pCI-neo background was assayed with pCIF and pCIR
primer pair that ampliﬁes both spliced (161 bp) and unspliced
(293 bp for pCI-neo transcript and 313 bp for pCI-neo + 20nt insert
transcript) species.
2.5. Real-time RT-PCR
After reverse transcription, cDNA was ampliﬁed in StepOne-
Plus™ real-time PCR System (Applied Biosystems) using Maxima™
SYBR Green/ROX qPCR Master Mix(2) (Fermentas) and speciﬁcprimers. HpRT1 and HpRT2 primer pair was used for ampliﬁcation
of cDNA from spliced species and HpRT11 and HpRT2 pair was
used for ampliﬁcation of total minigene cDNA. For standard curves
of Ct vs. log[RNA in ng], two step RT-PCR was performed on known
amounts of in vitro transcribed target RNA. The relative quantities
of spliced or total RNA in each sample under investigation were ob-
tained from the respective standard curves. Data shown here rep-
resents mean of at least three independent experiments with error
bar representing ±standard deviation. Student’s t-test was per-
formed with GraphPad Prism 5 software.
2.6. RNA stability assay
Twenty-four hours post transfection, cells were treated with
1 lg/ml Actinomycin D and kept at 37 C for indicated time and to-
tal RNA was extracted. The isolated RNA was analyzed by phos-
phorimager quantitation as described above. RNA levels were
normalized against GAPDH mRNA.
3. Results and discussion
3.1. The HBV intron contains a splicing silencer
To establish an in vitro system that recapitulates the splicing
regulation of HBV pre-mRNA, we designed minigenes under the
control of CMV-IE promoter and transfected them into HuH7 hu-
man hepatocarcinoma cell line. The CMV-IE promoter has been
shown to enhance the accumulation of spliced transcripts for ret-
roviral genes when compared to their endogenous promoters and
also for HBV where the combination of both CMV-IE promoter
and HuH7 cells as transfection hosts were noted to produce more
splice variant RNA [13]. We constructed a basal minigene (CPS,
as it includes regions from these three HBV genes) to recapitulate
splicing of HBV major spliced product SP1 and the HBSP mRNA
(Fig. 1). Both semiquantitative radioactive RT-PCR and real-time
RT-PCR analyses were carried out to elucidate the level of splicing
of the transcripts. We explored the secondary structure of the in-
tron of the minigene with MFOLD (http://www.bioinfo.rpi.edu/
applications/mfold) using default settings to give us idea about
the presence of structured regulatory motifs [14]. We concentrated
on an element spanning 2951–3163nt that was conserved in all the
predicted structural conformations of HBV intron in different free
Fig. 3. Splicing proﬁle of CPS and its deletion construct. (A) Removal of ISSL favors
splicing. Quantitative RT-PCR analysis shows two-fold splicing repression by ISSL.
All results are representative of minimum three independently performed exper-
iments. The histogram shows mean ± standard deviation. (B) Direct visualization of
spliced and total minigene transcripts also demonstrate enhanced splicing in
0
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both contiguous and distal sequences and formation of alternative
structural conformers seemed possible (Fig. 2). We posited that
formation of such alternative conformers could be linked to regu-
lation of pgRNA maturation and investigated whether splicing of
the transcribed pre-mRNA in transfected HuH7 cells was affected
by deletion of this structure from the minigene construct.
Real-time PCR analysis of the expressed RNA revealed that dele-
tion of this structured motif doubled the level of spliced RNA when
compared to CPS indicating presence of a splicing repressor domain
(Fig. 3A). As a complementary approach we looked directly at the
level of spliced and unspliced minigene transcripts by semiquanti-
tative RT-PCR followed by phosphorimaging (Fig. 3B). Increase in
the level of spliced products in deletion mutants further reinforced
our real-time RT-PCR observation. Accordingly we termed this
structured region as ISSL (intronic splicing silencer-long).
3.2. ISSL has separate activator and repressor domains
The increase in splicing upon deletion of ISSL led us to further
investigate the role of different sequence elements within it. We
progressively removed 20nt fragments from the 50end starting from
2951nt (Fig. 4A, upper panel) or speciﬁc 20nt fragments (lower pa-
nel). Our data indicated that the effect of ISSL is actually bipartite
and it contains both splicing activator and inhibitor domains
(Fig. 4B). Deletion of ﬁrst 20nt from the 50 end of ISSL inhibited splic-
ing to 10% of CPS implying its role as a splicing activator. Deletion of
next 20nt region on the other hand rescued splicing to almost the
same level of CPS. Further deletions upto 100nt from the 50 end of
ISSL (2951–3050nt of HBV) did not signiﬁcantly alter the level of
splicing. But deletion of immediate downstream sequence
(CPSISSLD2951–3070) abruptly caused the splicing to diminish toFig. 2. MFOLD generated secondary structure of ISSL. Note extensive base-pairing
within the region resulting in juxtaposition of distal sequences.
CPSDISSL. The asterisk indicates a minor spliced product SP3 that utilizes a weak 5 -
ss at 2471. In lanes 1–5, 10-fold decreasing amounts of target RNA were analyzed.almost an undetectable level. However further downstream dele-
tions in ISSL rescued inhibition. We named these intronic splicing
activators as ISA1 (2951–2970nt) and ISA2 (3051–3070nt) respec-
tively. Removal of sequences in the 30 end of ISSL signiﬁcantly in-
creased splicing (compare CPSISSLD2951–3130 with CPSDISSL)
implying that the 3131–3163nt of HBV harbors a splicing silencer.
Taken together our results indicate that the splicing repressor and
activator domains are distinct and scattered throughout ISSL.
To further characterize the role of these individual elements in
ISSL we deleted individual 20nt elements within ISSL (Fig. 4C).
While deletion of ISA1 and ISA2 regions were sufﬁcient to repress,
speciﬁc deletions of 3111–3130nt (ISR1) and 3131–3163nt (ISR2)
did not affect splicing appreciably. It is pertinent to note that re-
moval of 3111–3163nt terminal region in ISSL activates splicing
in absence of rest of ISSL but their speciﬁc removal does not have
any signiﬁcant effect. This possibly means that the terminal repres-
sor is squelched by rest of the sequence in ISSL by some unknown
mechanism.
3.3. Activator domains are still active in presence of PRE, long HBV
exon and in a heterologous context
Addition of PRE (CPSPRE) or almost entire 30 exon of SP1 (CPSpg)
downstream of CPS suppressed the level of splicing. Removal of
ISA1 or ISA2 in these backgrounds further diminished splicing efﬁ-
ciencies. In CPSPREDISA1 and CPSPREDISA2 transcripts, splicing
was reduced to 30% and 7%, respectively compared to CPS
(Fig. 5A), while that in CPSpgDISA1 and CPSpgDISA2 were 10%
and 17%, respectively (Fig. 5B). Therefore ISA1 and ISA2 activate
splicing in the presence of exonic sequences known to harbor other
splicing regulators.
Fig. 4. (A) Progressive deletions in ISSL. (A) Schematic of deletion constructs. A ﬁxed 50-half of the CPS was ligated to progressively truncated fragments of ISSL (ISSLD2951–
2970 to ISSLD2951–3130). Lower panel shows schematic of speciﬁc 20 bp deletion constructs. Locations of conjugate primer pairs for speciﬁc 20 bp deletions in ISSL are
indicated. (B) Real-time RT-PCR analysis showing deletion of 2951–2970nt and 3051–3070nt (ISA1 and ISA2) repressed splicing to 10% of basal minigene. Removal of 3131–
3163nt in ISSL showed maximum stimulation of splicing. (C) Real-time RT-PCR demonstrates splicing activation associated with ISA1 and ISA2. Deletion of only ISR1 or ISR2
marginally affected splicing.
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splicing by 3-fold and 7-fold, respectively, as revealed by semi-
quantitative analysis (data not shown), implying a generalized
splicing activator function even in a heterologus context. We also
ascertained that the stability of either the precursor or the spliced
RNA from different minigenes were similar (Fig. 5C).
3.4. Mutations interfere with 30 terminal repressor function
Intramolecular base-pairing between ISR1 and ISR2 suggests an
internal stem-loop structure (Fig. 6A). In this conformation, a stem-loop could form between two neighboring regions, 3118–3126nt
(GGAAGGCAG) and 3136–3143nt (CUGUCUCC). To investigate
whether formation of such stem is important for repression of
splicing, we mutated ISR2 (3138–3143nt; GUCUCC to UGUAGU)
to abolish interaction with ISR1. Our results demonstrate that
mutation in these sequences (ISSLMCPS) actually augmented
repression irrespective of presence of ISR1 (Fig. 6B). Therefore
3138–3143nt (GUCUCC) in ISR2 plays a crucial role in regulation
of splicing in HBV.
The interspersed presence of regulatory domains within ISSL
raises interesting possibilities. Firstly, ISA1 and ISA2 were immedi-
Fig. 5. Analysis of splicing activation by ISA1 and ISA2. Real-time RT-PCR shows deletion of either ISA1 or ISA2 in CPSPRE (A) or CPSpg (B) drastically reduces splicing. (C) The
stability of the spliced and precursor RNA of different minigenes were similar following treatment with 1 lg/ml Actinomycin D for indicated times.
Fig. 6. Mutation analysis of repressor domain. (A) ISR1 and ISR2 can form a stem-loop structure. The mutations (UGUAGU in bold) that disrupt such structure in ISSLMCPS are
shown. (B) Real-time RT-PCR analysis shows mutation of 3138–3143nt (GUCUCC to UGUAGU) results in strong repression of splicing in CPS and DISR1 constructs.
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could possibly determine the fate of pgRNA transcripts depending
on cognate cellular signals. The ability of ISA1 and ISA2 to activate
splicing in presence of PRE or the entire 30 exon and even in a het-erologous pre-mRNA indicates independent activator function.
Secondly, mutation of 3138–3143nt in ISR2 resulted in strong
repression of splicing (Fig. 6B). These sequences therefore attenu-
ate repression even being embedded within a repressor element.
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Our data depicts the presence of an intronic splicing regulator
domain in pgRNA with interspersed splicing activator and repres-
sor regions. The two intronic splicing activators, ISA1 and ISA2,
can possibly function as general splicing activators. On the other
hand, 3138–3143nt in ISR2 possibly attenuates repression. The
identiﬁcation of nuclear factors that recognize the individual RNA
elements and their correlation with status of HBV disease pathol-
ogy remains an important question.
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